Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Jasper Therapeutics's Briquilimab?
Briquilimab is a monoclonal antibody commercialized by Jasper Therapeutics, with a leading Phase II program in Severe Combined Immune Deficiency...
Data Insights
Briquilimab by Jasper Therapeutics for Chronic Urticaria Or Hives: Likelihood of Approval
Briquilimab is under clinical development by Jasper Therapeutics and currently in Phase II for Chronic Urticaria Or Hives. According to...